NCT00000221View on ClinicalTrials.gov

Alternate-Day Buprenorphine Administration. Phase I - 3

PHASE1CompletedINTERVENTIONAL

0

Timeline

Start Date

April 30, 1992

Conditions

Opioid-Related Disorders

Interventions

DRUG

Buprenorphine

Trial Locations (1)

05401

Treatment Research Center, Burlington

All Listed Sponsors

collaborator

University of Vermont

OTHER

lead

National Institute on Drug Abuse (NIDA)

NIH

NCT00000221 - Alternate-Day Buprenorphine Administration. Phase I - 3 | Biotech Hunter | Biotech Hunter